Next-Generation Cancer Treatment System with Targeted Human Growth Hormone Receptor Antagonists

A system for treating cancer with genetically engineered, cancer cell-specific human growth hormone receptor antagonists, enhancing the efficacy of chemotherapeutic agents and improving patient outcomes.

The original patent disclosed a composition and method for treating cancer using human growth hormone receptor antagonists. However, these antagonists lacked specificity, potentially leading to unwanted side effects. The new inventive concept addresses this limitation by engineering antagonists to selectively bind to cancer cells, reducing off-target effects and improving treatment outcomes.

The system comprises a genetically engineered human growth hormone receptor antagonist, designed to selectively bind to cancer cells expressing high levels of human growth hormone receptor. This antagonist is administered in coordination with a chemotherapeutic agent, enhancing the efficacy of the treatment. Additionally, the system includes a method for identifying patients likely to respond to this therapy, based on the expression levels of human growth hormone receptor, prolactin receptor, and ABC drug efflux pumps in cancer biopsy samples. A nanoparticle-encapsulated antagonist and a biosensor for monitoring treatment efficacy are also disclosed.

The new claims introduce a paradigm shift in cancer treatment by incorporating genetically engineered, cancer cell-specific antagonists, which is a significant departure from the original patent's composition-based approach. The selective binding of antagonists to cancer cells and the coordination with chemotherapeutic agents are novel and non-obvious aspects of the inventive concept.

Alternative embodiments of the system could include the use of different types of nanoparticles or targeted delivery systems for the antagonist, or the incorporation of additional biomarkers for patient selection. Variations of the biosensor could include different detection methods or formats, such as point-of-care devices or lab-based assays.

The next-generation cancer treatment system has significant commercial potential in the oncology market, with potential applications in various types of cancer, including breast, lung, and pancreatic cancer. The targeted approach and improved efficacy could lead to increased adoption and market share.